- Home
- HUCK vs PLX Comparison
HUCK vs PLX Comparison
Compare HUCK & PLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
N/A
Current Price
$3.14
SELL
Current Price
$2.75
Company Overview
Basic Information| Metric | HUCK | PLX |
|---|---|---|
| Founded | 2010 | 1993 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 159.5M | 182.9M |
| IPO Year | 2018 | 1996 |
Fundamental Metrics
Financial Performance| Metric | HUCK | PLX |
|---|---|---|
| Price | $3.14 | $2.75 |
| Analyst Decision | Hold | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $4.17 | N/A |
| AVG Volume (30 Days) | 717.8K | ★ 767.5K |
| Earning Date | 09-03-2026 | 08-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 31.92 | N/A |
| EPS | N/A | ★ 0.27 |
| Revenue | ★ $318,857,000.00 | $52,744,000.00 |
| Revenue This Year | N/A | $55.77 |
| Revenue Next Year | $1.33 | N/A |
| P/E Ratio | ★ N/A | $10.30 |
| Revenue Growth | ★ 0.57 | N/A |
| 52 Week Low | $3.03 | $1.60 |
| 52 Week High | $3.55 | $3.19 |
Technical Indicators
Market Signals| Indicator | HUCK | PLX |
|---|---|---|
| Relative Strength Index (RSI) | 23.66 | 57.33 |
| Support Level | $3.03 | $2.59 |
| Resistance Level | $3.45 | $2.85 |
| Average True Range (ATR) | 0.14 | 0.09 |
| MACD | -0.02 | -0.01 |
| Stochastic Oscillator | 19.13 | 73.83 |
Price Performance
Historical Comparison HUCK
PLX
About PLX Protalix BioTherapeutics Inc. (DE)
Protalix BioTherapeutics Inc is a commercial-stage biopharmaceutical company focused on the discovery, development, production, and commercialization of therapeutics for rare diseases with important unmet needs. ProCellEx, a proprietary plant cell-based protein expression system, represents a new method for developing recombinant proteins in an industrial-scale manner. corporate includes the development of treatments for rare and orphan diseases. The Company operates as a single operating segment in Israel.